Progen gets in synth

By Dylan Bushell-Embling
Wednesday, 02 July, 2008

Brisbane biotech Progen Pharmaceuticals (ASX: PGL) has spun out its manufacturing business into a wholly-owned subsidiary.

The new subsidiary will be called PharmaSynth, and will be responsible for completing Progen's PI-88 manufacturing process.

It will also offer process development and manufacturing services to the biotechnology industry.

Progen's former director of manufacturing operations, Les Tillack, is the new company's CEO.

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

Whyalla Steelworks sale enters final bidding round

Researchers turn captured carbon dioxide into valuable chemicals

Queensland launches tender for additional gas‍-‍fired generation

WA calls for expressions of interest to build defence manufacturing hub

Corvus Technology opens Victorian manufacturing facility

Epson renews fashion partnership

Renewable energy to power 4 million Aussie homes by 2030

Urban farming network provides sustainable food to CBD

Waste CO2 turned into useful industrial chemicals

Collaboration advances Digital Metering Program

How better people management systems can help aged care organisations thrive

Outdated, overused and ineffective — time to end mandatory double-checking?

New Support at Home consumer protection measures announced

Chemical-free cleaning: the future of infection control in health care

Latrobe Regional Health charged after nurse "seriously assaulted" by patient